Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + thalidomide + dexamethasone for relapsed or refractory multiple myeloma
ACTRN12615000818538Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib, thalidomide and dexamethasone in multiple myeloma (MM), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Progression-free survival. Started Mar 2017; status: completed.
02
Drugs
carfilzomibthalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12615000818538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000818538.